Ärztliches Team

Dr. med. Bernd Metzner

Leitender Arzt für Hochdosistherapie und autologe Stammzelltransplantation

Facharzt für Innere Medizin, Schwerpunkt Hämatologie und Internistische Onkologie

Telefon: (0441) 403-2614

Beruflicher Lebenslauf:

Veröffentlichungen:

1.  Risiko-adaptierte Therapie hochmaligner Non-Hodgkin Lymphome mit COP-BLAM/IMVP-16: Eine prospektive multizentrische Studie.  H.H. Gerhartz, W.Wilmanns, G. Brittinger, M. Engelhard, R. Heinz, D. Huhn, P. Meusers, W. Siegert, A. Stacher, E. Thiel, H. Dietzfelbinger, B. Doerken, W. Dornoff, W. Enne, R. Fuchs, J. Heise, W. Hettchen, K. Kabelitz, R. Kuse, E. Lengfelder, H. Löffler, B. Metzner, L. Nowicki, H. Radtke, M Schaefers, E. Schumacher, H. Seibt, H.J. Staiger, T. Wagner, M.G. Willems, K.H. Zurborn, T. Zwingers, A.C. Feller, C. v. Schilling, H. Stein, K. Lennert.
Onkologie (1989) 12:22-26

2.  Sprechen Knochenmetastasen auf eine Immuntherapie mit Interleukin-2 und Interferon-alpha-2b beim Nierenzellkarzinom an?  B. Metzner, R. Siegmund, H. Kirchner, J. Atzpodien, H.J. Illiger.  Tumordiagn Ther (1991) 12:192-196

3.  Cisplatin/ etoposide/ ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinoma.  A. Harstrick, H.-J. Schmoll, C. Bokemeyer, B Metzner, H.-J. Illiger, W. Berdel, H. Ostermann, C. Manegold, U. Räth, W. Siegert, R. Sonntag, R. Hartenstein, C. Clemm, H. Wilke, H. Poliwoda.  J Cancer Res Clin Oncol (1991) 117 (Suppl IV): 198-202

4.  Dose escalation of cisplatin, etoposide and ifosfamide with GM-CSF for advanced germ cell tumors.  H.-J. Schmoll, C. Bokemeyer, A.Harstrick, H.J. Illiger, B. Metzner, U. Rüther, H. Ostermann, J. Preiss, H. Wilke, J. Hohnloser, et al.   Pathol Biol Paris  (1992)  39:961

5.  A Phase I/II Study of a Stepwise Dose-escalated Regimen of Cisplatin, Etoposide and Ifosfamide plus Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) in Patients with Advanced Germ Cell Tumours.  C. Bokemeyer, H.-J. Schmoll, A. Harstrick, H.J. Illiger, B. Metzner, U. Räth, J. Hohnloser, C. Clemm, W. Berdel, W. Siegert, U. Rüther, H. Ostermann, M. Kneba, J.H. Hartlapp, M. Schröder, H. Poliwoda.
Eur J Cancer (1993) 29A:2225-2231

6.  Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide and ifosfamide in patients with advanced testicular cancer.  C. Bokemeyer, H.-J. Schmoll, B. Metzner, J. Beyer, H.J. Illiger, M. Kneba, H. Ostermann, B. Kynast, U. Rath, H. Poliwoda.  Ann Hematol  (1993)  67:75-79

7.  The Role of Granulocyte-Macrophage Colony-Stimulating Factor in the Treatment of Germ Cell Tumors.  C. Bokemeyer, A. Harstrick, U. Rüther, B. Metzner, H.J. Illiger, C. Clemm, W. Siegert, H. Link, H. Ostermann, H.-J. Schmoll. Seminars Oncology (1994) 21 (Suppl 16):57-63

8.  Zytostatika.  B. Metzner, H.J. Illiger.  in:  Hämatologie für Praxis und Klinik (Hrsg. R. Kuse)  Gustav Fischer Verlag Stuttgart Jena New York (1995) : 265-274

9.  Palliative und supportive Therapie.  B. Metzner, H.J. Illiger.  in:  Hämatologie für Praxis und Klinik  (Hrsg. R. Kuse) Gustav Fischer Verlag Stuttgart Jena New York  (1995) : 315-317

10.  Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progressive Metastatic Renal Cell Carcinoma.  J. Atzpodien, E.L. Hänninen, H. Kirchner, H. Bodenstein, M. Pfreundschuh, U. Rebmann, B. Metzner, H.J. Illiger, G. Jakse, T. Niesel, H.J. Scholz, S. Wilhelm, T. Pielmeier, G. Zakrzewski, G. Blum, J. Beier, G.W. Müller, S. Duensing, P. Anton, E. Allhoff, U. Jonas, H. Poliwoda. J Clin Oncology (1995) 13:497-501

11.  Phase II Study of Paclitaxel in Patients with Relapsed or Cisplatin-refractory Testicular Cancer.  C. Bokemeyer, J. Beyer, B. Metzner, U. Rüther, A. Harstrick, L. Weißbach, U. Köhrmann, W. Verbeek, H.-J. Schmoll.  Ann Oncol (1996) 7:31-34

12.  Improved Outcome in Adult B-Cell Acute Lymphoblastic Leukemia.  D. Hoelzer, W.D. Ludwig, E. Thiel, W. Gaßmann, H. Löffler, C. Fonatsch, H. Rieder, G. Heil, B. Heinze, R. Arnold, D. Hossfeld, T. Büchner, P. Koch, M. Freund, W. Hiddemann, G. Maschmeyer, A. Heyll, C. Aul, T. Faak, R. Kuse, T.H. Ittel, M. Gramatzki, H. Diedrich, K. Kolbe, H.G. Fuhr, K. Fischer, C. Schadeck-Gressel, A. Weiss, I. Strohscheer, B. Metzner, U. Fabry, N. Gökbuget, B. Völkers, D. Messerer, K. Überla.  Blood (1996) 87:495-508

13. High Dose Mitoxantrone with Thiotepa, Cyclophosphamide and Autologous Stem Cell Rescue for High Risk Stage II and Stage III Breast Cancer.  A.R. Zander, W. Krüger, N. Kröger, L. Damon, M. Königmann, W.E. Berdel, F. Gieseking, K. Schäfer-Eckart, V. Möbus, N. Frickhofen, H. Wandt, H.J. Illiger, B. Metzner, K. Kolbe, B. Wörmann, L. Trümper, C. Huber, D.K. Hossfeld, H. Maass, W. Jonat. 
Bone Marrow Transplantation (1996) 18, Suppl.1:S24-S25

14. Treatment of Brain Metastases in Patients with Testicular Cancer.  C. Bokemeyer, P. Nowak, A. Haupt, B. Metzner, H. Köhne, J.T. Hartmann, L. Kanz, H.-J. Schmoll. J Clin Oncol (1997) 15:1449-1454

15.  Therapie der B-ALL und lymphoblastischer B-NHL in den multizentrischen ALL-Studien des Erwachsenen.  D. Hoelzer, N. Gökbuget, W.D. Ludwig, E. Thiel, W. Gaßmann, H. Löffler, C. Fonatsch, H. Rieder, G. Heil, B. Heinze, R. Arnold, D. Hossfeld, T. Büchner, P. Koch, M. Freund, W. Hiddemann, G. Maschmeyer, A. Heyll, C. Aul, T. Faak, R. Kuse, T.H. Ittel, M. Gramatzki, H. Diedrich, K. Kolbe, H.G. Fuhr, K. Fischer, C. Schadeck-Gressel, A. Weiss, I. Strohscheer, B. Metzner, U. Fabry, B. Völkers, D. Messerer.
In: Maligne Lymphome - Biologie, Klassifikation und Klinik  (Hrsg. H.-G. Höffkes, M. Uppenkamp)  Springer-Verlag Berlin (1997) : 177-187

16.  A Phase I/II Study  of Sequential, Dose-Escalated, High Dose Ifosfamide plus  Doxorubicin with Peripheral Blood Stem Cell Support for the Treatment of Patients with Advanced Soft Tissue Sarcomas.  C. Bokemeyer, A. Franzke, J.T. Hartmann, C. Schöber, L. Arseniev, B. Metzner, H. Link, L. Kanz, H.-J. Schmoll.  Cancer (1997) 80:1221-1227

17. Detection of Melanoma Cells in Peripheral Blood Stem Cell Harvests of Patients with Progressive Metastatic Malignant Melanoma.  M. Probst-Kepper, A. Schrader, J. Buer, J. Grosse, M. Volkenandt, H.-J. Illiger, B. Metzner, J. Kadar, S. Duensing, B. Hertenstein, A. Ganser, J. Atzpodien.  British J. Haematology (1997) 98:488-490

18.  The Use of Dose-Intensified Chemotherapy in the Treatment of Metastatic Nonseminomatous  Testicular Germ Cell Tumors.  C. Bokemeyer, A. Harstrick, J. Beyer, B. Metzner, U. Rüther, J.T. Hartmann, K. Holstein, H.-G. Derigs, R. de Wit, J. Casper, P. Schöffski, I. Kührer, H.-J. Illiger, B. Kempf, A. Reichle, A. Föller, D.K. Hossfeld, J.T. Fischer, W.E. Berdel, H.H. Gerhartz, H. Kirchner, K.-H. Pflüger, H. Ostermann, L. Kanz, H.-J. Schmoll.    Sem. Oncol. (1998) 25, Suppl.4: 24-32

19.  First-Line High-Dose Chemotherapy for ‘Poor Risk’ Metastatic Non-Seminomatous Testicular Germ Cell Tumors.  C. Bokemeyer, A. Harstrick, J. Beyer, B. Metzner, U. Rüther, J.T. Hartmann, K. Holstein, H.-G. Derigs, R. de Wit, J. Casper, P. Schöffski, I. Kührer, H.-J. Illiger, B. Kempf, A. Reichle, A. Föller, D.K. Hossfeld, J.T. Fischer, W. Berdel, H. Gerhartz, H. Kirchner, K. Pflüger, H. Ostermann, L. Kanz, H.-J. Schmoll.  Onkologie (1998) 21, Suppl.2: 23-25

20.  First-Line High-Dose Chemotherapy Compared With Standard-Dose PEB/VIP Chemotherapy in Patients With Advanced Germ Cell Tumors: A Multivariate and Matched-Pair Analysis.  C. Bokemeyer, C. Kollmannsberger, C. Meisner, A. Harstrick, J. Beyer, B. Metzner, J.T. Hartmann, H.-J. Schmoll, L. Einhorn, L. Kanz, C. Nichols. J. Clin. Oncol. (1999) 17: 3450-3456

21.  Early Infectious Complications after High-Dose Therapy and Autologous Blood Stem Cell Transplantation.  B. Metzner, R. Dirks, W. Gebauer, D. Reschke, T.H. Müller, E. Ost, D. Reichert, B. Rosien, F. del Valle, I. Zirpel, J. Hellkamp, K.P. Kohse, F. Schunter, H.J. Illiger. Onkologie (1999) 22: 491-496

22.  Treatment of Patients With Cisplatin-Refractory Testicular Germ-Cell Cancer. German Testicular Cancer Study Group (GTCSG).  C. Bokemeyer, C. Kollmannsberger, A. Harstrick, J. Beyer, A. Gerl, J. Casper, B. Metzner, J.T. Hartmann, H.J. Schmoll, L. Kanz. Int. J. Cancer (1999) 83: 848-851

23.  ASHAP - an Effective Salvage Therapy for Recurrent and Refractory Malignant Lymphomas.  M. Hänel, N. Kröger, M.M. Hoffknecht, S.O. Peters, B. Metzner, F. Fiedler, D. Braumann, J.C. Schubert, H.J. Illiger, A. Hänel, W.H. Krüger, W. Zeller, H.J. Weh, D.K. Hossfeld, A.R. Zander    Ann. Hematol. (2000) 79: 304-311

24. Optimal CD34(+) Cell Dose in Autologous Peripheral-Blood Stem-Cell Transplantation.  O. Sezer, K. Possinger, B. Metzner, H.J. Illiger, M. Wattad, W. Heit, H. Fuss, W. Schultze.  J. Clin. Oncol. (2000) 18: 3319-3320

25.  Dose-Dependent Effect of Etoposide in Combination with Busulfan Plus Cyclophosphamide as Conditioning for Stem Cell Transplantation in Patients with Acute Myeloid Leukemia.  N. Kröger, T. Zabelina, S. Sonnenberg, W. Krüger, H. Renges, N. Stute, F. Finkenstein, U. Mayer, K. Holstein, W. Fiedler, H. Colberg, R. Sonnen, R. Kuse, D. Braumann, B. Metzner, F. del Valle, R. Erttmann, H. Kabisch, A.R. Zander. Bone Marrow Transplantation (2000) 26: 711-716

26.  Determination of Cytokeratin-Expressing Cells in Blood, Bone Marrow and Blood Progenitor Cell Products.  W. Gebauer, E. Fallgren-Gebauer, I. Barklage, B. Metzner, F. Schunter.  In: Proceedings of the Forth International Stem Cell Workshop: High-Dose Therapy and Transplantation of Haematopoietic Stem Cells (Editor: W. Schultze) Blackwell Verlag Berlin – Vienna (2000): 98-100

27.  Salvage Treatment With Paclitaxel, Ifosfamide and Cisplatin Plus High-Dose Carboplatin, Etoposide and Thiotepa Followed by Autologous Stem-Cell Rescue in Patients With Relapsed or Refractory Germ Cell Cancer.  O. Rick, C. Bokemeyer, J. Beyer, J.T. Hartmann, N. Schwella, D. Kingreen, S. Neureither, B. Metzner, J. Casper, H. Wandt, F. Hartmann, H.J. Schmoll, G. Derigs, A. Gerl, W.E. Berdel, L. Kanz, W. Siegert. J. Clin. Oncol. (2001) 19: 81-88

28.  Clinical Impact of Germ Cell Tumor Cells in Apheresis Products of Patients Receiving High-Dose Chemotherapy.  C. Bokemeyer, A.J. Gillis, K. Pompe, F. Mayer, B. Metzner, N. Schleucher, J. Schleicher, G. Pflugrad-Jauch, JW Oosterhuis, L. Kanz, L.H. Looijenga. J. Clin. Oncol. (2001) 19: 3029-3036

29.  IL-2 in Combination with IFN-α and 5-FU versus Tamoxifen in Metastatic Renal Cell Carcinoma: Long-term Results of a Controlled Randomized Clinical Trial.  J. Atzpodien, H. Kirchner H.J. Illiger, B. Metzner, D. Ukena, H. Schott, P.J. Funke, M. Gramatzki, S. von Jürgenson, T. Wandert, T. Patzelt, M. Reitz, DGCIN (German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group)   Brit. J. Cancer (2001) 85: 1130-1136

30.  Busulfan, Cyclophosphamide, and Etoposide as high-dose conditioning regimen in patients with malignant lymphoma.  M. Hänel, N. Kröger, S. Sonnenberg, M. Bornhäuser, W. Krüger, F. Kroschinsky, A. Hänel, B. Metzner, J. Birkmann, B. Schmidt, M.M. Hoffknecht, F. Fiedler, G. Ehninger, A.R. Zander   Ann. Hematol. (2002) 81: 96-102

31.  Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer.  C. Bokemeyer, K. Oechsle, J.T. Hartmann, P. Schöffski, N. Schleucher, B. Metzner, J. Schleicher, L. Kanz.  Brit. J. Cancer (2002) 87: 1066-1071

32. Rituximab zur Remissionsinduktion bei rezidivierten und refraktären indolenten Lymphomen und Mantelzell-Lymphomen.  R. Forstpointner, A. Hänel, R. Repp, S. Hermann, B. Metzner, C. Pott, F. Hartmann, F. Rothmann, H.P.Böck, H. Wandt, M. Unterhalt, W. Hiddemann.  Dtsch. Med. Wochenschr. (2002) 127: 2253-2258

33.  Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for “Aggressive” Lymphoma.  U. Kaiser, I. Uebelacker, U. Abel, J. Birkmann, L. Trümper, H. Schmalenberg, T. Karakas, B. Metzner, D.K. Hossfeld, H.G. Bischoff, A. Franke, M. Reiser, P. Müller, L. Mantovani, M. Grundeis, F. Rothmann, C.-U. v. Seydewitz, R.M. Mesters, E.U. Steinhauer, D. Krahl, K. Schumacher, M. Kneba, M. Baudis, N. Schmitz, R. Pfab, H. Köppler, R. Parwaresch, M. Pfreundschuh, K. Havemann. 
J. Clin. Oncol. (2002) 20: 4413-4419

34.  Späte infektiöse Komplikationen nach Hochdosistherapie und autologer Blutstammzelltransplantation.  B. Metzner, R. Grüneisl, W. Gebauer, D. Reschke, E. Ost, T.H. Müller, D. Reichert, B. Rosien, F. del Valle, I. Zirpel, K.P. Kohse, F. Schunter, H.-J. Illiger. Med. Klin. (2002) 97: 650-658

35.  Analysis of Salvage Treatments for Germ Cell Cancer Patients Who Have Relapsed After Primary High-Dose Chemotherapy Plus Autologous Stem Cell Support. C. Kollmannsberger, N. Schleucher, O. Rick, B. Metzner, J.T. Hartmann, P. Schoffski, J. Beyer, J. Casper, M. Sosada, H.J. Schmoll, I. Bohlke, C. Meisner, L. Kanz, C. Bokemeyer. Eur J Cancer (2003) 39 : 775-82

36.  First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial. C. Bokemeyer, N. Schleucher, B. Metzner, M. Thomas, O. Rick, H.-J. Schmoll, C. Kollmannsberger, I. Boehlke, L. Kanz, J.T. Hartmann. British J. Cancer (2003) 89: 29-35

37.  Stem Cell Transplantation in Acute Myeloid Leukemia after Conditioning with Busulfan, Cyclophosphamide and Different Dosages of Etoposide (VP-16).  N. Kröger, T. Zabelina, S. Sonnenberg, W. Krüger, H. Renges, N. Stute, F. Finkenstein, U. Mayer, K. Holstein, W. Fiedler, H. Colberg, R. Sonnen, R. Kuse, D. Braumann, B. Metzner, F. del Valle, R. Erttmann, H. Kabisch, A.R. Zander. In: Transplantation in Hematology and Oncology II. (Hrsg.: W.E. Berdel, H. Jürgens, Th. Büchner, J. Ritter, J. Kienast, J. Vormooor)  Springer-Verlag Berlin (2003): 219-227

38.  Recombinant human erythropoietin, epoietin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy – results of a randomized trial. J.P. Glossmann, A. Engert, G. Wassmer, H. Flechtner, Y. Ko, C. Rudolph, B. Metzner, B. Dörken, S. Wiedenmann, V. Diehl, A. Josting.  Ann Hematol. (2003) 82: 469-475

39.  High-Dose Therapy for Patients With Primary Multifocal and Early Relapsed Ewing´s Tumors: Results of Two Consecutive Regimens Assessing the Role of Total-Body Irradiation.  S. Burdach, A. Meyer-Bahlburg, H.J. Laws, R. Haase, B. van Kaik, B. Metzner, A. Wawer, R. Finke, U. Göbel, J. Haerting, H. Pape, H. Gadner, J. Dunst, H. Juergens. J. Clin. Oncol. (2003) 21: 3072-3078

40.  A new conditioning regimen involving total marrow irradiation, busulfan and cyclophophamide followed by autologous PBSCT in patients with advanced multiple myeloma. H. Einsele, M. Bamberg, W. Budach, H. Schmidberger, C.F. Hess, B. Wörmann, C. Meisner, C. Straka, H. Hebart, L. Trümper, N. Kröger, A.R. Zander, S. Hegewisch-Becker, D.K. Hossfeld, H. Schmidt, P. Müller, G. Schlimok, B. Hertenstein, D. Peest, B. Metzner, N. Frickhofen, L. Kanz, W.I. Bensinger.  Bone Marrow Transplantation (2003) 32: 593-599

41.  Long-Term Results of First-Line Sequential High-Dose Etoposide, Ifosfamide, and Cisplatin Chemotherapy Plus Autologous Stem Cell Support for Patients With Advanced Metastatic Germ Cell Cancer: An Extended Phase I/II Study of the German Testicular Cancer Study Group.  H.-J. Schmoll, C. Kollmannsberger, B. Metzner, J.T. Hartmann, N. Schleucher, P. Schöffski, J. Schleicher, O. Rick, J. Beyer, D. Hossfeld, L. Kanz, W.E. Berdel, R. Andreesen, C. Bokemeyer.  J. Clin. Oncol. (2003) 21: 4083-4091

42.  Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group.  C. Kollmannsberger, J. Beyer, R. Liersch, P. Schöffski, B. Metzner, J.T. Hartmann, O. Rick, K. Stengele, K. Hohloch, C. Spott, L. Kanz, C. Bokemeyer. J. Clin. Oncol. (2004) 22: 108-114

43.  Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). 
Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Muller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M; Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol. 2004 Apr 1;22(7):1188-94.

44.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rube C, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group.
Blood. 2004 Aug 1;104(3):626-33.

45.  High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial.
Zander AR, Kroger N, Schmoor C, Kruger W, Mobus V, Frickhofen N, Metzner B, Schultze W, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Trumper L, Kreienberg R, Carstensen M, Schmidt EH, Janicke F, Schumacher M, Jonat W.
J Clin Oncol. 2004 Jun 15;22(12):2273-83.

46.  Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.
Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, Hess G, Truemper L, Diehl V, Kropff M, Kneba M, Schmitz N, Metzner B, Pfirrmann M, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group.
Blood. 2004 Nov 1;104(9):2667-74.

47.  The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Bock HP, Wandt H, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group.
Blood. 2004 Nov 15;104(10):3064-71.

48.  Early consolidation by myelo